Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Teva (NYSE: TEVA) announced that Richard Francis, Teva president and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026.
The presentation starts at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time). A live webcast will be available on Teva’s investor relations website and an archived recording will be posted within 24 hours and remain accessible for up to 30 days.
Positive
- None.
Negative
- None.
News Market Reaction 25 Alerts
On the day this news was published, TEVA gained 0.16%, reflecting a mild positive market reaction. Our momentum scanner triggered 25 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $60M to the company's valuation, bringing the market cap to $37.73B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: UTHR up 1.36%, VTRS down 0.32%, with others near flat. NBIX and UTHR also announced J.P. Morgan Healthcare Conference presentations, indicating a conference-driven news cluster rather than a unified sector price move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 24 | Ratings upgrade | Positive | +0.6% | Credit rating upgrade and positive outlook tied to deleveraging and growth. |
| Dec 19 | Biosimilar settlement | Positive | +0.1% | Settlement setting U.S. entry date for AVT06, an Eylea biosimilar. |
| Dec 12 | Earnings call notice | Neutral | +1.1% | Announcement of Q4 2025 results release and investor conference call. |
| Dec 12 | Investor materials | Neutral | +1.1% | Posting Q4 2025 Aide Memoire to guide investors before results. |
| Dec 09 | NDA submission | Positive | +0.8% | FDA NDA filing for once-monthly olanzapine LAI for schizophrenia. |
Recent news—ratings upgrades, pipeline/regulatory steps, and informational updates—has generally seen modest, positive price alignment.
Over the past month, Teva has reported several constructive developments. On Dec 9, 2025, it filed an NDA for TEV-'749 supported by positive Phase 3 data. On Dec 12, 2025, it prepared investors for Q4 2025 results with an aide memoire and call scheduling. A ratings upgrade from S&P and a positive outlook shift from Moody’s followed on Dec 24, 2025. A late-December biosimilar settlement for AVT06 added another strategic milestone. Today’s conference participation notice fits this pattern of ongoing engagement with investors and stakeholders.
Market Pulse Summary
This announcement highlights Teva’s participation at the 44th Annual J.P. Morgan Healthcare Conference, with the CEO presenting on January 13, 2026. Investors gain structured access via a live webcast and a 30-day archive. In the weeks leading up to this, Teva reported an NDA filing, ratings upgrades, and a biosimilar settlement, indicating active strategic and financial developments. Investors may focus on how management updates these themes and any commentary that could frame the upcoming Q4 2025 earnings release.
AI-generated analysis. Not financial advice.
TEL AVIV, Israel, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026. The presentation will begin at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time).
To access a live webcast of the presentation, visit Teva’s Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations.
An archived version of the webcast will be available within 24 hours after the end of the live discussion and will be accessible for up to 30 days.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This document and the presentation at the conference may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding our financial guidance, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. These forward-looking statements include statements concerning our plans, strategies, objectives, future performance and financial and operating targets, and any other information that is not historical information. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; our ability to develop and commercialize additional pharmaceutical products; competition for our innovative medicines; our ability to achieve expected results from investments in our product pipeline; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, to sustain and focus our portfolio of generic medicines, and to execute on our organizational transformation and to achieve expected cost savings; and the effectiveness of our patents and other measures to protect our intellectual property rights; our significant indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in this document, in our Quarterly Report on Form 10-Q for the third quarter of 2025 and in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the sections captioned “Risk Factors” and “Forward-looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
Teva Media Inquiries
TevaCommunicationsNorthAmerica@tevapharm.com
Teva Investor Relations Inquires
TevaIR@Tevapharm.com
FAQ
When will Teva (TEVA) present at the 44th Annual J.P. Morgan Healthcare Conference?
What time is Teva's (TEVA) presentation on January 13, 2026?
Who will present for Teva (TEVA) at the J.P. Morgan Healthcare Conference?
How can investors watch Teva's (TEVA) live presentation on January 13, 2026?
Will Teva's (TEVA) presentation be available after the live event?
Where is the archived webcast of Teva's (TEVA) presentation posted?
